The online healthcare market in India is buzzing with competition, but two giants stand out- Tata 1mg and Pharmeasy. If you’ve ever ordered medicines online or booked a diagnostic test from the comfort of your home, chances are you’ve come across these two platforms.
But when it comes to Tata 1mg vs Pharmeasy, who’s really winning the Indian market?
Let’s look into their journey, features, and financials to find out!
Profile Overview
Both Tata 1mg and Pharmeasy are big names in the healthcare and e-commerce sectors. Founded in the same year, 2015, these companies have grown rapidly, but their approaches differ significantly.
| Particulars | Tata 1mg | PharmEasy |
| Industry | Healthcare; E-commerce; Information Technology; Retail | Healthcare; E-commerce; Information Technology; Retail |
| Products | Medicine Supply; Healthcare Products | Medicinal Products |
| Services | Online pharmacy; Online doctor; Diagnostic; E-consultation; Lab blood test | Medicine delivery; Healthcare services |
| Founders | Prashant Tandon (CEO); Vikas Chauhan; Gaurav Agarwal | Dharmil Sheth; Dhaval Shah; Harsh Parekh; Siddharth Shah; Hardik Dedhia |
| Founding Year | 2015 | 2015 |
| Headquarters | Gurugram (Haryana, India) | Mumbai (Maharashtra, India) |
| Tagline | “Understandable, Accessible, and Affordable” | “Take it easy Pharmeasy” |
| Type of Brand | B2C (Business-to-Consumer) | B2C (Business-to-Consumer) |
| Parent Company | Tata Digital | API Holdings Limited |
Tata 1mg
Headquartered in Gurugram, Tata 1mg was established by Prashant Tandon, Vikas Chauhan, and Gaurav Agarwal. Backed by Tata Digital, its tagline, “Understandable, Accessible, and Affordable,” reflects its mission to simplify healthcare for everyone. It offers a wide range of services like online pharmacy, e-consultations, lab tests, and diagnostic services.
We have covered the business model here- “How does Tata 1mg make money? Full Business Model Explained.”
Pharmeasy
Based in Mumbai, Pharmeasy was founded by Dharmil Sheth, Dhaval Shah, Harsh Parekh, Siddharth Shah, and Hardik Dedhia. Known for its catchy tagline, “Take it easy Pharmeasy,” the platform initially focused on medicine delivery but later expanded into lab tests and healthcare services. It operates under API Holdings Limited.
Here is the business model- “How does Pharmeasy make money? Business Model in Detail.”
When you compare Tata 1mg vs Pharmeasy in terms of branding and services, both are strong players. However, the backing of the Tata Group gives Tata 1mg a distinct advantage in terms of credibility and scalability.
Features Comparison: Tata 1mg vs Pharmeasy
When it comes to user experience and convenience, both platforms have their strengths and weaknesses. Here’s how-
| Features | Tata 1mg | Pharmeasy |
| Delivery Options | Free home delivery; local pharmacy pickup available | Click-and-pick model; home delivery available |
| Prescription Upload | Allows QR code or image uploads for prescriptions | Requires prescription uploads for certain medications |
| Promotional Offers | Frequent discounts and promotional campaigns | Limited marketing spend; focus on sustainable growth |
| Revenue Model | Medicine sales, lab tests, advertising services | Primarily from medicine sales and lab tests |
| Focus on Profitability | Aiming for overall profitability soon | Restructuring for profitability; reduced marketing efforts |
| Mobile App Features | User-friendly app with health-tracking tools and reminders | Comprehensive app with medicine reminders and consultation booking |
| Customer Support | 24/7 customer support via chat and phone | Customer support available via chat and phone during business hours |
| Payment Options | Multiple payment methods including UPI, cards, wallets; and Cash on Delivery | Supports UPI, cards, wallets, and cash on delivery |
| Health Content | Extensive health articles, blogs, and advice from professionals | Comparatively limited health content |
| Lab Test Integration | Integrated lab test booking with home sample collection options | Lab tests available with home sample collection; an extensive network of labs |
Highlights
- Delivery Options: Tata 1mg provides free home delivery and even offers a local pharmacy pickup option. Pharmeasy has a similar home delivery service, but it also includes a click-and-pick model for convenience.
- Prescription Uploads: Tata 1mg allows you to upload prescriptions via QR codes or images, making the process seamless. On the other hand, Pharmeasy mandates prescription uploads for certain medications, which can sometimes be a hassle.
- Mobile App: Tata 1mg’s app is highly user-friendly, featuring health-tracking tools and reminders to keep you organized. Pharmeasy’s app focuses more on medicine reminders and consultation bookings but lacks additional features like health tracking.
- Promotional Offers: If you’re on the lookout for discounts, Tata 1mg frequently rolls out promotional campaigns. Pharmeasy, however, has been cutting back on marketing expenses to focus on sustainable growth.
- Customer Support: Both platforms offer chat and phone support, but Tata 1mg operates 24/7, while Pharmeasy’s service is only available during business hours.
In the Tata 1mg vs Pharmeasy debate, Tata 1mg clearly edges ahead in terms of app features, customer support, and marketing campaigns.
Business Comparison of Tata 1mg vs Pharmeasy
The financial side of things tells a compelling story about the competitive dynamics of these companies.
| Financial Aspects | Tata 1mg | Pharmeasy |
| Market Valuation | $1.25 billion | $458 million |
| Market Share (as of 2023) | 31% | 15% |
| User Base (monthly) | 40 million | 17 million |
| Revenue | Rs.1,968 crore (US $230 million) | Rs.5,664 crore |
| Total Expenses | Rs.2,303 crore | Rs.7,254.8 crore |
| Profit/Loss | Loss of Rs.313 crore | Loss of Rs.2,553.5 crore |
Let’s summarize it-
- Market Share and Valuation: As of 2023, Tata 1mg holds a commanding 31% market share with a valuation of $1.25 billion. In contrast, Pharmeasy’s market share has dwindled to 15%, and its valuation has plummeted by 92%, from $5.6 billion in 2021 to just $458 million in 2023.
- Revenue and Losses: Pharmeasy might lead in revenue at Rs.5,664 crore compared to Tata 1mg’s Rs.1,968 crore, but it also faces enormous losses—Rs.2,553.5 crore compared to Tata 1mg’s Rs.313 crore.
Pharmeasy’s aggressive acquisition of Thyrocare for Rs.4,546 crore didn’t pan out as expected, with Thyrocare’s EBITDA halving and its market cap plunging by over 60%. Add to that rising losses and a Rs.3,500 crore loan default, and Pharmeasy’s financial troubles only deepen.
On the other hand, Tata 1mg seems to be on a steady path toward profitability, thanks to its balanced approach and Tata Digital’s strong backing.
Why Pharmeasy is Struggling?
Pharmeasy’s meteoric rise seemed unstoppable until 2021, but things quickly took a turn. Its valuation nosedived, its market share shrank from 33% to 15%, and its IPO plans were shelved. But why?
Due to the following reasons-
- Debt Burden: Pharmeasy defaulted on a massive Rs.3,500 crore loan from Goldman Sachs.
- Overambitious Acquisitions: The Thyrocare acquisition backfired, leading to financial instability.
- Competition: The entry of Tata 1mg, along with players like Flipkart, Reliance, and Apollo, has intensified the market.
- Rising Losses: In FY23 alone, Pharmeasy reported losses of Rs.5,211 crore.
- Allegations of Mis-selling: Reports of mis-selling practices further tarnished its reputation.
What sets Tata 1mg apart?
Tata 1mg’s strategy revolves around stability and growth. By leveraging the Tata brand’s credibility, it has managed to secure a loyal customer base of 40 million monthly users. Unlike Pharmeasy, Tata 1mg has avoided risky acquisitions and focused on building a sustainable business model.
- Integrated Services: From e-consultations to lab tests, Tata 1mg offers a one-stop solution for healthcare needs.
- Health Content: Its extensive blogs and advice from professionals educate users, adding more value.
- User-Friendly App: Health-tracking tools and reminders make the app stand out.
- Marketing Strength: Frequent promotional campaigns keep customers engaged and loyal.
The Future of Tata 1mg and Pharmeasy
The Tata 1mg vs Pharmeasy rivalry highlights the evolving dynamics of India’s healthcare sector. Tata 1mg appears to be the clear winner for now, thanks to its strong financials, innovative features, and robust market share. Pharmeasy, on the other hand, faces an uphill battle to regain its footing.
With Tata 1mg aiming for overall profitability soon, its position in the market is only expected to strengthen. Meanwhile, Pharmeasy will need to address its financial woes and rethink its strategy to remain competitive.
Final Words
When you compare Tata 1mg vs Pharmeasy, the numbers, features, and strategies tell a clear story. Tata 1mg is not just winning the market but setting the standard for online healthcare services in India. Whether you’re looking for convenience, reliability, or value for money, Tata 1mg seems to check all the boxes.
Pharmeasy, with its strong foundation, still has potential, but it must navigate its financial challenges carefully. For now, the crown belongs to Tata 1mg. The question is, can Pharmeasy turn the tide?
Only time will tell.
The post Tata 1mg vs Pharmeasy: Who is the Winner? appeared first on The Business Rule.